Results of an international Phase III trial demonstrate that the new targeted oral drug, regorafenib, which targets angiogenic, stromal and oncogenic receptor tyrosine kinase, can improve outcomes for patients with gastrointestinal stromal tumors (GIST) that progress due to resistance to other available treatment options, including imatinib (Gleevec®, Novartis) and sunitinib (…

Continue

Researchers re-analyzing the results of a large phase III study of patients with advanced neuroendocrine tumors (NET) found that certain factors, such as bone metastases, having NETs that originate in the lung, and elevated levels of the blood biomarker chromogranin A predict which individuals are at greatest risk for neuroendocrine tumor progression and are more likely to need active therapy. The results of the study were presented at the 9th Annual Gastrointestinal Cancers…

Continue

A new fourth-generation oncolytic virus designed to both kill cancer cells and inhibit blood-vessel growth has shown greater effectiveness than earlier versions when tested in animal models of human brain cancer.



Researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) are developing the oncolytic…

Continue

A new fourth-generation oncolytic virus designed to both kill cancer cells and inhibit blood-vessel growth has shown greater effectiveness than earlier versions when tested in animal models of human brain cancer.



Researchers at the Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) are developing the oncolytic…

Continue

The first patients have been dosed in a new Phase I dose-escalation clinical study to evaluate NKTR-102, Nektar Therapeutics' lead oncology compound, in combination with 5-fluorouracil (5-FU)/leucovorin in refractory solid tumor cancers. The study is being conducted at University Hospitals Case Medical Center of the Case Comprehensive Cancer Center in Cleveland, Ohio.



NKTR-102, a novel topoisomerase I inhibitor-polymer conjugate compound, was invented by…

Continue

Groundbreaking studies will be presented at the ESMO 12^th World Congress on Gastrointestinal Cancer next week in Barcelona, Spain, including exciting new data on treatment for neuroendocrine tumors. “The presentations this year are very significant for clinicians, and outline real progress in the development of agents that are effective in managing and treating gastrointestinal diseases,” says Eric Van Cutsem, MD, PhD of the University Hospital Gasthuisberg in Leuven,…

Continue

A great number of the world's preeminent gastroenterologists will gather during the seventh annual Gastrointestinal Cancers Symposium (ASCO GI) from January 22-24, 2010, at the Orlando World Center Marriott to discuss new research on the treatment of gastrointestinal cancers.



Presentations at the meeting will focus on detection and treatment of gastrointestinal cancers, which includes cancers of the colon/rectum, stomach, pancreas, esophagus, small intestine, anus and… Continue

The U.S. Food and Drug Administration, in late December 2008, approved imatinib mesylate (Glivec®, Novartis AG, Lichtstrasse 35, 4056 Basel, Switzerland and Gleevec®, Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, NJ) for the post-surgery treatment of adult patients following complete surgical removal of KIT (CD117)-positive gastrointestinal stromal tumors (GIST).



The tyrosine kinase inhibitor imatinib mesylate is now the only post-surgery treatment… Continue